BE555319A - - Google Patents

Info

Publication number
BE555319A
BE555319A BE555319DA BE555319A BE 555319 A BE555319 A BE 555319A BE 555319D A BE555319D A BE 555319DA BE 555319 A BE555319 A BE 555319A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of BE555319A publication Critical patent/BE555319A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE555319D 1956-03-21 BE555319A (instruction)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US572788A US2868691A (en) 1956-03-21 1956-03-21 Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine

Publications (1)

Publication Number Publication Date
BE555319A true BE555319A (instruction) 1900-01-01

Family

ID=24289356

Family Applications (1)

Application Number Title Priority Date Filing Date
BE555319D BE555319A (instruction) 1956-03-21

Country Status (3)

Country Link
US (1) US2868691A (instruction)
BE (1) BE555319A (instruction)
GB (1) GB830426A (instruction)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051621A (en) * 1959-10-22 1962-08-28 Grove Lab Inc Gel composition, pressurized container with same, and method of preparation
US3050443A (en) * 1960-02-16 1962-08-21 James F Schuyler Headache remedy containing ammonia
US3039928A (en) * 1960-03-17 1962-06-19 Abbott Lab Stable aqueous isoproteronol compositions
NL262354A (instruction) * 1960-03-17
US3088874A (en) * 1960-05-23 1963-05-07 Union Carbide Corp Powder aerosol
US3282781A (en) * 1960-11-25 1966-11-01 Merck & Co Inc Inhalant compositions
BE632504A (instruction) * 1962-05-24
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
NL302251A (instruction) * 1963-01-28 1965-10-11
US3710782A (en) * 1969-10-01 1973-01-16 Hauser Res And Eng Co Method of treating human skin with a composition for electromedical applications
IL51314A (en) * 1976-01-30 1980-03-31 Fisons Ltd Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
AU522792B2 (en) * 1977-07-19 1982-06-24 Fisons Plc Pressure pack formulation
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
US4655231A (en) * 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
US4576949A (en) * 1984-05-07 1986-03-18 The Upjohn Company Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
EP0213108A3 (de) * 1985-06-26 1987-07-15 Kurt Dr. Burghart Pharmazeutische Zubereitung mit einem Antihypotonikum als wirksames Mittel
JPH0645538B2 (ja) * 1987-09-30 1994-06-15 日本化薬株式会社 ニトログリセリンスプレー剤
FR2625677A1 (fr) * 1988-01-07 1989-07-13 Cosnier Alain Composition medicamenteuse destinee a etre administree sous forme d'aerosol
DE68915203T2 (de) * 1988-03-22 1994-09-22 Fisons Plc, Ipswich, Suffolk Pharmazeutische Mischungen.
US5776434A (en) * 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
YU59192A (sh) 1991-06-10 1994-12-28 Schering Corporation Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
DE69205177T2 (de) * 1991-12-12 1996-03-21 Glaxo Group Ltd., Greenford, Middlesex Pharmazeutische Aerosolformulierung.
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
CA2125666C (en) 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
ES2159678T3 (es) 1991-12-18 2001-10-16 Minnesota Mining & Mfg Formulaciones de aerosol en suspension.
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
CA2151383C (en) * 1992-12-09 2005-02-08 Paul Donald Jager Stabilized medicinal aerosol solution formulation
ES2113574T3 (es) * 1993-06-01 1998-05-01 Ono Pharmaceutical Co Derivados del acido pentanoico.
EP0640609A1 (en) * 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
CA2137106C (en) * 1993-12-03 2000-02-08 Hisao Nakai Amidinophenol derivatives
NZ276637A (en) * 1993-12-20 1997-07-27 Minnesota Mining & Mfg Aerosol containing flunisolide, ethanol, and tetrafluoroethane and/or heptafluoropropane propellant
DK0703216T3 (da) 1994-09-20 1999-10-18 Ono Pharmaceutical Co Amidinophenolderivater som proteaseinhibitorer
US5679287A (en) * 1995-04-28 1997-10-21 Great Lakes Chemical Corporation Uses of heptafluoropropane
US5840213A (en) * 1995-04-28 1998-11-24 Great Lakes Chemical Corporation Uses of heptafluoropropane
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
EP0757984B1 (en) * 1995-08-08 2002-10-30 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives useful for inhibiting gelatinase
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5861268A (en) * 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
DK1014943T3 (da) 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US7153866B1 (en) * 1997-05-27 2006-12-26 The United States Of America As Represented By The Department Of Health And Human Services Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
JPH11187882A (ja) 1997-12-26 1999-07-13 Ono Pharmaceut Co Ltd 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｃＤＮＡ、そのｃＤＮＡからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
DE59904648D1 (de) 1998-08-04 2003-04-24 Jago Res Ag Muttenz Medizinische aerosolformulierungen
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
PL367740A1 (en) 2001-07-23 2005-03-07 Ono Pharmaceutical Co, Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
NZ534712A (en) 2002-02-19 2006-11-30 Ono Pharmaceutical Co Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
EP1534235B1 (en) 2002-06-25 2016-07-27 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
ES2464157T3 (es) 2002-06-26 2014-05-30 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades causadas por contracción o dilatación vascular
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
AU2003272962A1 (en) * 2002-10-10 2004-05-04 Shuh Narumiya Remedies for allergic diseases
TW200413000A (en) 2002-10-10 2004-08-01 Ono Pharmaceutical Co Intrinsic repair factor producing accelerator
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
BRPI0408332A (pt) 2003-03-14 2006-03-21 Ono Pharmaceutical Co derivados heterocìclicos contendo nitrogênio e medicamentos contendo os mesmos como ingrediente ativo
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
US20050107306A1 (en) * 2003-05-16 2005-05-19 Barr Philip J. Treatment of respiratory disease associated with matrix metalloproteases by inhalation of synthetic matrix metalloprotease inhibitors
WO2006031210A1 (en) * 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
US20070270489A1 (en) 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
EP2883865B1 (en) 2003-08-29 2019-09-25 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
MXPA06002152A (es) 2003-09-01 2006-05-22 Ono Pharmaceutical Co Compuesto de anillo condensado y uso del mismo.
JP2007505136A (ja) * 2003-09-10 2007-03-08 マツプ・フアーマシユーテイカルズ・インコーポレーテツド ジヒドロエルゴタミンを肺吸入により体循環に送達するためのエアゾール製剤
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
EP2308562B1 (en) 2003-12-25 2015-02-25 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2006004646A1 (en) * 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
ES2750600T3 (es) 2004-10-21 2020-03-26 Ono Pharmaceutical Co Uso de un receptor inmunosupresor
KR101158603B1 (ko) * 2004-11-24 2012-07-09 알콘, 인코퍼레이티드 비강용 스프레이를 전달하는 방법
WO2006084041A2 (en) 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing diabetes
CA2608273C (en) 2005-05-18 2015-10-20 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524735B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PL2656860T3 (pl) 2005-06-17 2021-11-08 Wisconsin Alumni Research Foundation Preparaty środka zwężającego naczynia i sposoby ochrony komórek podczas chemioterapii i radioterapii przeciwnowotworowej
WO2007049771A1 (ja) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
EP1961745A1 (en) 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
WO2007069671A1 (ja) 2005-12-15 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
CN104188907A (zh) 2007-02-11 2014-12-10 Map药物公司 治疗性施用dhe用于快速减轻偏头痛而使副作用分布最小化的方法
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
DE102008007198A1 (de) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
PT2346509T (pt) 2008-10-07 2020-08-05 Horizon Orphan Llc Inalação de levofloxacina para redução da inflamação pulmonar
AU2009302478B2 (en) 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
JP5621771B2 (ja) 2009-06-17 2014-11-12 小野薬品工業株式会社 新規なイミダゾピリジン化合物
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
HUE045469T2 (hu) 2009-09-04 2019-12-30 Horizon Orphan Llc Aeroszolizált levofloxacin alkalmazása cysticus fibrosis kezelésére
WO2011066537A1 (en) 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
PH12012502486A1 (en) 2010-06-21 2019-07-10 Ono Pharmaceutical Co New crystalline forms of 4,4`-[4-fluoro-7-([4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl)ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4`-[2-methyl-7-([4-[4-(pentafluorophenyl)butoxy]phenyl)ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4`-[4-fluoro-2-methyl-7-([4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl]ethynyl)-1h-indole-1,3-diyl]dibutanoic acid
ES2529129T3 (es) 2010-12-02 2015-02-17 Ono Pharmaceutical Co., Ltd. Nuevo compuesto y uso médico del mismo
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2012127885A1 (ja) 2011-03-18 2012-09-27 小野薬品工業株式会社 テトラヒドロカルボリン誘導体
JP6160613B2 (ja) 2012-04-26 2017-07-12 小野薬品工業株式会社 Ｔｒｋ阻害化合物
WO2014129431A1 (ja) 2013-02-19 2014-08-28 小野薬品工業株式会社 Ｔｒｋ阻害化合物
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
WO2015115673A1 (en) 2014-01-31 2015-08-06 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
US20210100886A1 (en) 2017-03-30 2021-04-08 Sumitomo Dainippon Pharma Co., Ltd. Wt1 cancer antigen peptides and peptide conjugates comprising the peptides
WO2019049891A1 (ja) 2017-09-06 2019-03-14 小野薬品工業株式会社 Ｔｒｋ阻害剤とキナーゼ阻害剤の併用による癌治療方法
MX2020012939A (es) 2018-05-31 2021-02-15 Ono Pharmaceutical Co Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
TW202446772A (zh) 2018-10-11 2024-12-01 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
PH12022550244A1 (en) 2019-08-05 2022-12-12 Nat Cancer Ct Biomarkers for determining the efficacy of immune checkpoint inhibitors
US20230014137A1 (en) 2019-11-29 2023-01-19 Ono Pharmaceutical Co., Ltd. Compound having lysophosphatidic acid receptor agonist activity and pharmaceutical use thereof
CA3167312A1 (en) 2020-02-07 2021-08-12 Stephen J. Lewis Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
WO2021205631A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 Ｓｔｉｎｇ作動化合物
US20230183316A1 (en) 2020-05-12 2023-06-15 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2022251679A1 (en) 2021-05-27 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide radicals for use as antiviral treatment for coronavirus infection
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222976A (en) * 1937-11-15 1940-11-26 Sharp & Dohme Inc Nasal drops
US2728495A (en) * 1951-04-19 1955-12-27 Little Inc A Liquid dispensing device and composition therefor

Also Published As

Publication number Publication date
GB830426A (en) 1960-03-16
US2868691A (en) 1959-01-13

Similar Documents

Publication Publication Date Title
AT2036B (instruction)
AT12077B (instruction)
AT14210B (instruction)
AT12855B (instruction)
AT12751B (instruction)
AT11979B (instruction)
AT2540B (instruction)
AT12104B (instruction)
AT12123B (instruction)
AT12140B (instruction)
AT12216B (instruction)
AT12326B (instruction)
AT12417B (instruction)
AT12485B (instruction)
AT12519B (instruction)
AT1712B (instruction)
AT12595B (instruction)
AT12707B (instruction)
AT2478B (instruction)
AT2477B (instruction)
AT2433B (instruction)
AT11687B (instruction)
AT2431B (instruction)
AT2339B (instruction)
AT2021B (instruction)